Terlipressin (Terlivaz): Uses, Evidence, and Side Effects

Patients with sudden kidney decline linked to liver disease face a serious condition called hepatorenal syndrome. Terlipressin, sold as Terlivaz, is a prescription option developed specifically to address this problem.

Key takeaways

• Terlipressin is a synthetic vasopressin analogue approved to improve kidney function in hepatorenal syndrome with rapid kidney decline.
• It carries a boxed warning, meaning prescribers and patients should be aware of its serious risk profile.
• Patients with a serum creatinine above 5 mg/dL are unlikely to benefit from treatment.
• Over 130 clinical trials have studied terlipressin, including work in variceal hemorrhage and hepatorenal syndrome.
• Reported adverse events include kidney-related complications, gastrointestinal symptoms, and cardiac rhythm changes, based on post-marketing reports.

What Terlipressin Is

Terlipressin belongs to a drug class called vasopressin receptor agonists. It is a synthetic version of vasopressin with roughly twice the selectivity for V1 receptors compared to V2 receptors. The compound works partly as a prodrug that converts into lysine-vasopressin in the body, while also having its own direct pharmacologic effects. In patients with hepatorenal syndrome, it is thought to increase renal blood flow by reducing portal hypertension and raising effective arterial volume and mean arterial pressure. The compound is identified in chemical databases under PubChem CID 72081.

What Terlipressin Is Approved For

Terlivaz is approved to improve kidney function in adults with hepatorenal syndrome accompanied by a rapid reduction in kidney function. The label notes a limitation of use: patients with a serum creatinine greater than 5 mg/dL are unlikely to experience benefit from treatment. Terlivaz carries a boxed warning, indicating the FDA has flagged serious risks that require careful clinical attention.

What the Evidence Shows

More than 130 clinical trials have investigated terlipressin across various conditions. One completed trial compared 24-hour versus 72-hour terlipressin therapy alongside endoscopic band ligation. A separate Phase 4 trial examined terlipressin plus albumin against albumin alone for treating hepatorenal syndrome, though that study was suspended. Other research, including a Phase 3 trial on terlipressin infusion for variceal hemorrhage, has explored its use beyond the approved indication.

Reported Side Effects

Post-marketing reports submitted to the FDA's adverse event system highlight several patterns, though these figures reflect report counts rather than confirmed incidence or direct causation. Kidney-related complications appear frequently, including renal impairment and acute kidney injury (19 and 17 reports respectively), along with cases of ascites (22 reports). Diarrhoea was also commonly reported (19 reports). Cardiac and systemic concerns appear as well, with QT prolongation and multiple organ dysfunction syndrome each cited 17 times. Reports of drug ineffectiveness (40) and off-label use (18) were also logged, reflecting real-world usage patterns beyond the approved population.